Bifogade filer
Kurs
-1,46%
Likviditet
2,54 MSEK
Prenumeration
Kalender
Tid* | ||
2026-02-27 | 08:00 | Bokslutskommuniké 2025 |
2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-22 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-06 | N/A | Årsstämma |
2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
2024-11-05 | - | Kvartalsrapport 2024-Q3 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2024-05-07 | - | Årsstämma |
2024-05-03 | - | Kvartalsrapport 2024-Q1 |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2023-05-11 | - | Årsstämma |
2023-05-04 | - | Kvartalsrapport 2023-Q1 |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2022-05-11 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-05 | - | Kvartalsrapport 2021-Q1 |
2021-03-05 | - | Extra Bolagsstämma 2021 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-06 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-05-22 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2020-05-20 | - | Årsstämma |
2020-05-05 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-08-23 | - | Kvartalsrapport 2019-Q2 |
2019-05-16 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2019-05-15 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2019-01-07 | - | Extra Bolagsstämma 2018 |
2018-10-19 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-06-13 | - | Årsstämma |
2018-05-09 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2018-05-08 | - | Kvartalsrapport 2018-Q1 |
2018-02-21 | - | Bokslutskommuniké 2017 |
2017-10-19 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-11 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2017-05-10 | - | Årsstämma |
2017-05-10 | - | Kvartalsrapport 2017-Q1 |
2017-03-27 | - | Extra Bolagsstämma 2017 |
2017-02-24 | - | Bokslutskommuniké 2016 |
2016-10-13 | - | Kvartalsrapport 2016-Q3 |
2016-07-08 | - | Kvartalsrapport 2016-Q2 |
2016-04-27 | - | Årsstämma |
2016-04-15 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | X-dag ordinarie utdelning VICO 0.00 SEK |
2016-02-25 | - | Bokslutskommuniké 2015 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Stockholm, April 12, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:
- Kempen Life Sciences Conference
Location: Amsterdam, Holland
Date: April 16
Company Participants: Hans Jeppsson, CFO, and Bertil Lindmark, CMO
- Aktiespararna - Digital Temadag - Life Science
Location: Virtual
Presenter: Mikael Nygård, VP Operations and Corporate Strategy
Presentation Date and Time: April 17 at 9:20 AM ET/3:20 PM CET
Webcast: https://www.aktiespararna.se/aktiviteter/digital-temadag---life-science-47005
For further information, please contact:
Ahmed Mousa, CEO, tel: +1 607 437 0235, ahmed.mousa@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
This information was submitted for publication on April 12, 2024, at 11:00 CET.
About Vicore Pharma Holding AB (publ)
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.